Michael W. Deininger mostly deals with Imatinib, Imatinib mesylate, Myeloid leukemia, Internal medicine and Cancer research. Michael W. Deininger has included themes like Cytarabine, Chronic myelogenous leukemia, Pharmacology and Drug resistance in his Imatinib study. His studies in Imatinib mesylate integrate themes in fields like Molecular biology, ABL and Bone marrow.
His Myeloid leukemia research is classified as research in Immunology. His Internal medicine research is multidisciplinary, relying on both Gastroenterology, Surgery and Oncology. His Cancer research research incorporates elements of Megakaryoblastic leukemia, Tyrosine kinase, Philadelphia chromosome and Tyrosine-kinase inhibitor.
Michael W. Deininger spends much of his time researching Cancer research, Imatinib, Internal medicine, Myeloid leukemia and Leukemia. His studies deal with areas such as Tyrosine kinase, ABL, Kinase activity, Stem cell and Philadelphia chromosome as well as Cancer research. His study brings together the fields of Chronic myelogenous leukemia and Imatinib.
He combines subjects such as Gastroenterology and Oncology with his study of Internal medicine. His Myeloid leukemia research is within the category of Immunology. His Leukemia study combines topics from a wide range of disciplines, such as Hematology, Cell culture, Chronic myelomonocytic leukemia and Drug resistance.
His primary scientific interests are in Internal medicine, Cancer research, Myeloid leukemia, Oncology and Imatinib. In the field of Internal medicine, his study on Bosutinib, Adverse effect and Nilotinib overlaps with subjects such as In patient. His research integrates issues of Cell culture, Apoptosis, Bcr abl1, Stem cell and Leukemia in his study of Cancer research.
His Myeloid leukemia research also works with subjects such as
Michael W. Deininger mainly focuses on Internal medicine, Myeloid leukemia, Cancer research, Leukemia and Myeloid. He has researched Internal medicine in several fields, including Gastroenterology and Oncology. His Myeloid leukemia research is multidisciplinary, incorporating elements of Tyrosine kinase and Philadelphia chromosome.
His Philadelphia chromosome research focuses on subjects like Cumulative incidence, which are linked to Dasatinib. His Cancer research research includes themes of Progenitor cell, Apoptosis, ABL, Tyrosine-kinase inhibitor and Allosteric regulation. Michael W. Deininger combines subjects such as Cancer and Pharmacology with his study of Imatinib.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann.
The New England Journal of Medicine (2006)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus.
The molecular biology of chronic myeloid leukemia
Michael W. N. Deininger;John M. Goldman;Junia V. Melo.
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek;Ruben A. Mesa;Jason Gotlib;Richard S. Levy.
The New England Journal of Medicine (2012)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani;Giuseppe Saglio;John Goldman;Andreas Hochhaus.
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser.
Journal of Clinical Oncology (2009)
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
Charles L. Sawyers;Andreas Hochhaus;Eric Feldman;John M. Goldman.
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
Michael Deininger;Elisabeth Buchdunger;Elisabeth Buchdunger;Elisabeth Buchdunger;Brian J. Druker;Brian J. Druker;Brian J. Druker.
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Moshe Talpaz;Richard T. Silver;Brian J. Druker;John M. Goldman.
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
Thomas O'Hare;Denise K. Walters;Eric P. Stoffregen;Taiping Jia.
Cancer Research (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: